Zicam Cold And Flu-like Symptoms

Dosage for Echinacea Angustifolia Whole is highly individualized, especially when used for immunotherapy.

• Initial Phase: Typically starts at a very low concentration (e.g., 0.01 mL to 0.1 mL of a 1:100,000 w/v dilution).
• Maintenance Phase: Gradually increased over several weeks to a maintenance dose, often ranging from 0.5 mL of a 1:100 w/v concentration.

Pediatric use must be strictly supervised by a pediatric allergist. Dosing is usually based on the child's sensitivity level rather than weight, starting at significantly lower concentrations than adult protocols.

Renal Impairment

No specific dosage adjustments are typically required for mild renal impairment, but cautious monitoring is advised for patients with severe kidney disease due to altered elimination of metabolic byproducts.

Hepatic Impairment

Patients with significant hepatic dysfunction should be monitored for increased sensitivity to the adrenergic components of the extract.

Elderly Patients

Lower starting doses may be considered for geriatric patients to minimize the risk of cardiovascular stress related to the adrenergic agonist activity.

• Administration: Most clinical forms are administered via subcutaneous injection in a medical setting capable of treating anaphylaxis.
• Observation: Patients must remain in the clinic for at least 30 minutes following administration to monitor for adverse reactions.
• Storage: Store in a refrigerator between 2°C and 8°C (36°F - 46°F). Do not freeze.

If a dose is missed, contact your healthcare provider immediately. Do not double the next dose. Missing a dose during the buildup phase of immunotherapy may require a reduction in the next dose to ensure safety.

Signs of overdose include severe tachycardia (rapid heart rate), hypertension, or systemic allergic reactions (hives, difficulty breathing). In case of suspected overdose, seek emergency medical attention or contact a poison control center immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

• Injection Site Reactions: Redness, itching, or swelling at the site of administration. This usually subsides within 24 to 48 hours.
• Mild Fatigue: A feeling of tiredness or lethargy following treatment.
• Nasal Congestion: Temporary stuffiness or sneezing.

• Headache: Mild to moderate tension-type headaches.
• Nausea: Occasional gastrointestinal upset.
• Generalized Itching: Itching that occurs away from the injection site.

• Tachycardia: An abnormally rapid heartbeat due to the adrenergic agonist properties.
• Hypotension: A sudden drop in blood pressure.
• Lymphadenopathy: Swelling of the lymph nodes.

> Warning: Stop taking Echinacea Angustifolia Whole and call your doctor immediately if you experience any of these:

• Anaphylaxis: A severe, life-threatening allergic reaction characterized by swelling of the throat, difficulty breathing, and fainting.
• Angioedema: Deep swelling under the skin, particularly around the eyes, lips, or throat.
• Chest Pain: Potential cardiovascular strain related to beta-adrenergic stimulation.
• Severe Wheezing: Sudden onset of asthma-like symptoms.

Prolonged use in immunotherapy is generally well-tolerated; however, chronic stimulation of adrenergic receptors may lead to minor changes in resting heart rate or blood pressure in sensitive individuals.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Echinacea Angustifolia Whole, as an allergenic extract, can cause severe life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma or those taking beta-blockers may be at increased risk.

Report any unusual symptoms to your healthcare provider.

Echinacea Angustifolia Whole must be used with extreme caution in patients with a history of severe asthma or autoimmune disorders. Because it contains adrenergic agonists, it may interfere with medications used to manage heart disease or blood pressure.

According to FDA standards for allergenic extracts, this product carries a warning regarding the risk of Anaphylaxis. Administration must occur in a clinical setting with immediate access to epinephrine and emergency resuscitative equipment.

• Allergic Reactions: There is a constant risk of systemic allergic reactions. Patients should be screened for sensitivity to other members of the Asteraceae (Compositae) family, such as ragweed or daisies.
• Cardiovascular Risk: Due to its alpha and beta-adrenergic agonist activity, it may cause palpitations or increased blood pressure.
• Autoimmune Conditions: Use with caution in patients with multiple sclerosis, lupus, or rheumatoid arthritis, as immune stimulation could potentially exacerbate these conditions.

• Observation: 30-minute post-injection observation is mandatory.
• Lung Function: Baseline and periodic peak flow or spirometry for patients with asthma.
• Vital Signs: Monitoring of blood pressure and heart rate during the buildup phase.

Patients should avoid driving or operating heavy machinery for several hours after an injection if they experience dizziness or fatigue.

Alcohol should be avoided on the day of treatment as it can dilate blood vessels and potentially increase the rate of absorption of the extract, elevating the risk of a systemic reaction.

Do not stop immunotherapy abruptly without consulting your allergist, as this may result in a loss of the desensitization achieved and increase the risk of reaction upon restarting.

> Important: Discuss all your medical conditions with your healthcare provider before starting Echinacea Angustifolia Whole.

• Non-Selective Beta-Blockers: Drugs like propranolol can block the effects of epinephrine, making it difficult to treat a severe allergic reaction if one occurs during treatment.
• MAO Inhibitors: Combining Echinacea Angustifolia Whole (which has adrenergic activity) with MAOIs can lead to a hypertensive crisis (dangerously high blood pressure).

• Tricyclic Antidepressants: May potentiate the pressor effects of the adrenergic components in the extract.
• Other Adrenergic Agonists: Concurrent use with stimulants or decongestants may increase the risk of tachycardia and hypertension.

• Immunosuppressants: Medications like cyclosporine or corticosteroids may reduce the effectiveness of the allergenic extract by suppressing the intended immune response.

• Caffeine: High intake of caffeine may exacerbate the stimulant effects of the beta-adrenergic components, leading to jitters or palpitations.

• St. John's Wort: May alter the metabolism of certain components of the extract through CYP450 induction.
• Ephedra/Ma Huang: Should be avoided due to additive cardiovascular stimulant effects.

Echinacea Angustifolia Whole may interfere with the results of Skin Allergy Tests for other substances if administered recently. It may also transiently affect white blood cell counts due to its immune-stimulating properties.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted values are at high risk for fatal bronchospasm.
• Recent Myocardial Infarction: Due to adrenergic agonist activity, use is contraindicated in patients who have had a heart attack within the last 3-6 months.
• Known Hypersensitivity: Previous anaphylactic reaction to Echinacea species or any component of the formulation.

• Autoimmune Disorders: The risk of stimulating the immune system must be weighed against the benefits of allergy desensitization.
• Pregnancy: Generally not initiated during pregnancy, though maintenance doses may sometimes be continued.

Patients allergic to other members of the Asteraceae family (including ragweed, chrysanthemums, marigolds, and daisies) may experience cross-reactive allergic symptoms when treated with Echinacea Angustifolia Whole.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Echinacea Angustifolia Whole.

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. It is generally recommended that immunotherapy not be initiated during pregnancy due to the risk of maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen). If a patient becomes pregnant while on a maintenance dose, the physician may choose to continue treatment at a stable or reduced dose.

It is unknown if the components of Echinacea Angustifolia Whole pass into breast milk. Caution should be exercised, and the potential for infant exposure to allergenic proteins should be discussed with a healthcare provider.

Safety and effectiveness in children under the age of 5 have not been fully established for all indications. In older children, it is used for immunotherapy under strict specialist supervision, with careful monitoring for effects on growth and development.

Elderly patients (over 65) may have a higher prevalence of cardiovascular disease, making them more susceptible to the side effects of the beta-adrenergic agonist components. Renal clearance of metabolites may also be reduced.

No specific dose adjustment is defined, but patients with a GFR < 30 mL/min should be monitored for signs of systemic toxicity.

Use with caution in patients with Child-Pugh Class B or C hepatic impairment, as the metabolism of alkylamides and other active fractions may be delayed.

> Important: Special populations require individualized medical assessment.

Echinacea Angustifolia Whole acts as an immunomodulator by interacting with Type 1 and Type 2 Cannabinoid receptors (CB1 and CB2) on immune cells, particularly through its alkylamide constituents. As a Standardized Insect Venom Allergenic Extract [EPC], it induces the production of IgG4 blocking antibodies, which compete with IgE for allergen binding. Its Adrenergic Agonist [MoA] properties involve direct stimulation of alpha-1, beta-1, and beta-2 receptors, influencing systemic hemodynamics.

• Onset of Effect: Immunological changes begin within hours, but clinical desensitization typically takes 6-12 months of consistent therapy.
• Duration: Effects can last for years after a completed 3-5 year course of immunotherapy.

| Parameter | Value |

|---|---|

| Bioavailability | < 20% (Oral); ~90% (Subcutaneous) |

| Protein Binding | Variable (30-70%) |

| Half-life | 2-6 hours (active alkylamides) |

| Tmax | 1-2 hours (Subcutaneous) |

| Metabolism | Hepatic (CYP3A4 involvement suspected) |

| Excretion | Renal 70%, Fecal 20% |

• Molecular Formula: Complex mixture (includes C12H19NO for specific alkylamides).
• Molecular Weight: Varies by component.
• Solubility: Partially soluble in water; highly soluble in ethanol-water mixtures.

Echinacea Angustifolia Whole is classified as a Standardized Allergenic Extract. It is related to other botanical and venom-based immunotherapies used in clinical allergy and immunology.